Metraipolis › archive › dc_c03da7febad8

What role for real-world evidence in market access of biosimilars? — Europe PMC PMID:40066332

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40066332
DOI
10.3389/fphar.2025.1538866
License (as archived)
solo-consultazione
Archived
2026-10-06T16:03:29.935Z
SHA-256 of the archived text
990c640da3bd67d45e4e01fee44c3d557a7f61fc9fb6c575b26a7d17148c5155
Stable URL of this page
https://metraipolis.com/documento/dc_c03da7febad8

How to cite

What role for real-world evidence in market access of biosimilars? — Europe PMC PMID:40066332 — Europe PMC (en), https://europepmc.org/article/MED/40066332 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c03da7febad8 (Metraipolis archive dc_c03da7febad8, sha256 990c640da3bd67d45e4e01fee44c3d557a7f61fc9fb6c575b26a7d17148c5155)
BibTeX
@misc{dcc03da7febad8,
  title = {What role for real-world evidence in market access of biosimilars? — Europe PMC PMID:40066332},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40066332},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c03da7febad8; sha256 990c640da3bd67d45e4e01fee44c3d557a7f61fc9fb6c575b26a7d17148c5155},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40066332. Agents can read the archived copy with the MCP tool read_document.